ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤ASCENIV revenue $124.7 million, increasing 31% year-over-year
- ➤FY2026 revenue guidance reiterated at least $530 million
- ➤FY2026 Adjusted EBITDA outlook raised to at least $275 million
- ➤GAAP net income $49.9 million, increasing 37% year-over-year
- ➤FDA feedback supports SG-001 clinical strategy and planned IND submission
Expert Statements
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“Our third quarter results demonstrate ADMA’s ability to translate accelerating ASCENIV demand into substantial earnings growth”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“ASCENIV revenue increased 31% year-over-year, driven by expanding physician adoption, new patient starts and growing end-user utilization.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“Favorable demand trends have continued into the fourth quarter, highlighting the durability of ASCENIV’s growth trajectory and significant remaining market opportunity.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“We are also encouraged by signs of stabilization in underlying BIVIGAM utilization, despite competitive pressures in the standard immune globulin market.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“Together with expanding margins and substantial per-share earnings growth, we believe these trends demonstrate the scalability and increasing profitability of our business.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“Our expanding real-world health outcomes evidence strengthens ASCENIV’s clinical value proposition among medically complex primary immunodeficiency patients and supports growing commercial adoption.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“With our yield-enhanced manufacturing capabilities, robust cash generation and disciplined capital allocation, we believe ADMA is well positioned to deliver sustained, profitable growth and long-term stockholder value creation.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“We are reiterating our full-year revenue outlook while increasing our minimum expectations for Adjusted Net Income and Adjusted EBITDA and continue to advance SG-001 as a potential additional long-term growth opportunity.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“We are also encouraged by the constructive FDA feedback recently received on our SG-001 pre-IND meeting package, which we believe represents an important milestone for the program.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“Notably, we received constructive feedback from the FDA regarding the proposed clinical development strategy, including key elements of the planned clinical study.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“Based on the FDA’s feedback, we intend to incorporate the recommendations into the final clinical protocol and advance preparations for an IND submission.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“The FDA also indicated that our proposed assay would be acceptable for product testing, subject to appropriate validation.”
Adam Grossman, President and Chief Executive Officer of ADMA Biologics
“We believe this feedback supports a potentially efficient development pathway that leverages ADMA’s established manufacturing capabilities and clinical development experience as we advance SG-001 toward clinical trials.”
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year
3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year
Get started
Create a free account to read the full story.